PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: JPMorgan Raises Derwent, Cuts Shaftesbury

Fri, 15th Jan 2021 09:38

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

----------

FTSE 100

----------

UBS CUTS BT GROUP TO 'SELL' ('NEUTRAL') - TARGET 111 (116) PENCE

----------

LIBERUM RAISES WHITBREAD PRICE TARGET TO 3,000 (2,400) PENCE - 'HOLD'

----------

MORGAN STANLEY RAISES MELROSE INDUSTRIES TARGET TO 148 (140) PENCE - 'EQUAL-WEIGHT'

----------

DEUTSCHE BANK CUTS COCA-COLA HBC PRICE TARGET TO 2,800 (2,850) PENCE - 'BUY'

----------

DEUTSCHE BANK CUTS DIAGEO PRICE TARGET TO 3,850 (3,900) PENCE - 'BUY'

----------

BERENBERG RAISES DIAGEO PRICE TARGET TO 3,080 (2,810) PENCE - 'HOLD'

----------

JPMORGAN RAISES SEGRO PRICE TARGET TO 910 (880) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES LAND SECURITIES PRICE TARGET TO 800 (650) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES BRITISH LAND PRICE TARGET TO 500 (430) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES BP PRICE TARGET TO 415 (400) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ROYAL DUTCH SHELL PRICE TARGET TO 1,800 (1,700) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RESUMES TESCO WITH 'OVERWEIGHT' - TARGET 300 PENCE

----------

JPMORGAN RAISES BARCLAYS PRICE TARGET TO 180 (160) PENCE - 'OVERWEIGHT'

----------

DEUTSCHE BANK REINITIATES ASTRAZENECA WITH 'BUY' - PRICE TARGET 10,000 PENCE

----------

DEUTSCHE BANK REINITIATES GLAXOSMITHKLINE WITH 'HOLD' - PRICE TARGET 1,400 PENCE

----------

FTSE 250

----------

JPMORGAN RAISES WORKSPACE GROUP PRICE TARGET TO 855 (820) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES ST MODWEN PROPERTIES TARGET TO 445 (390) PENCE - 'OVERWEIGHT'

----------

JPMORGAN RAISES LONDONMETRIC PROPERTY PRICE TARGET TO 230 (220) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS HAMMERSON PRICE TARGET TO 25 (30) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES GREAT PORTLAND PRICE TARGET TO 700 (630) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS CAPITAL & COUNTIES PRICE TARGET TO 135 (150) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN CUTS UNITE GROUP TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 950 PENCE

----------

JPMORGAN CUTS SHAFTESBURY TO 'UNDERWEIGHT' ('NEUTRAL') - TARGET 550 (900) PENCE

----------

JPMORGAN RAISES DERWENT LONDON TO 'NEUTRAL' ('UNDERWEIGHT') TARGET 3,200 (2,850) PENCE

----------

CREDIT SUISSE CUTS WOOD GROUP PRICE TARGET TO 320 (350) PENCE - 'NEUTRAL'

----------

BERENBERG RAISES WOOD GROUP PRICE TARGET TO 400 (290) PENCE - 'BUY'

----------

LIBERUM RAISES HOWDEN JOINERY GROUP PRICE TARGET TO 780 (760) PENCE - 'BUY'

----------

JPMORGAN CUTS BABCOCK INTERNATIONAL PRICE TARGET TO 270 (335) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS BABCOCK INTERNATIONAL PRICE TARGET TO 355 (430) PENCE - 'BUY'

----------

MORGAN STANLEY RAISES IMI PRICE TARGET TO 1,400 (1,320) PENCE - 'OVERWEIGHT

----------

DEUTSCHE BANK CUTS BRITVIC PRICE TARGET TO 930 (955) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES 888 HOLDINGS PRICE TARGET TO 340 (320) PENCE - 'BUY'

----------

RBC CUTS VESUVIUS TO 'SECTOR PERFORM' ('OUTPERFORM') - TARGET 550 (480) PENCE

----------

RBC CUTS BODYCOTE TO 'SECTOR PERFORM' ('OUTPERFORM') - TARGET 770 (710) P

----------

OTHER MAIN MARKET AND AIM

----------

CREDIT SUISSE RAISES BOOHOO PRICE TARGET TO 350 (300) PENCE - 'NEUTRAL'

----------

LIBERUM RAISES BOOHOO PRICE TARGET TO 380 (350) PENCE - 'HOLD'

----------

JEFFERIES RAISES LSL PROPERTY SERVICE PRICE TARGET TO 280 (243) PENCE - 'HOLD'

----------

DEUTSCHE BANK CUTS FEVERTREE DRINKS PRICE TARGET TO 2,525 (2,550) PENCE - 'HOLD'

----------

JPMORGAN RAISES HELICAL TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 485 (460) PENCE

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.